Article

8 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    7 8 0 0


Annales de Dermatologie et de Vénéréologie
Volume 142, n° 8-9
pages 476-482 (août 2015)
Doi : 10.1016/j.annder.2015.06.013
Hémangiomes infantiles : quand explorer et actualités thérapeutiques
Infantile haemangioma: When investigation is necessary and current therapeutic developments
 

C. Eschard
 Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Köenig, 51092 Reims cedex, France 

Résumé

L’hémangiome infantile (HI) est la plus fréquente des tumeurs bénignes de l’enfant. Dans la majorité des cas le diagnostic est essentiellement clinique et, en raison de son involution naturelle, sans séquelle majeure, en quelques années, l’abstention thérapeutique est de règle. Certaines investigations complémentaires sont cependant parfois nécessaires quand la clinique est atypique ou porte à confusion, en cas de retentissement possible sur des structures avoisinantes ou à distance, et enfin à la recherche d’anomalies associées dans certaines formes syndromiques qu’il faut savoir reconnaître. Elles permettent de mieux cerner les indications thérapeutiques pour des hémangiomes susceptibles de se compliquer. L’actualité thérapeutique a été marquée par la découverte récente de l’efficacité spectaculaire des β-bloquants (propranolol) sur la cinétique du développement de l’hémangiome infantile, qui a transformé le pronostic de ces hémangiomes à risque.

The full text of this article is available in PDF format.
Summary

Infantile haemangioma (IH) is the most frequent benign tumour seen in children. In most cases, diagnosis is made chiefly on clinical grounds, and because the condition tends to subside naturally within several years and without any major sequelae, therapeutic abstention is the rule. However, a number of additional investigations may be necessary: where the clinical picture is atypical or potentially confusing, where the condition may affect adjacent or remote structures, in screening for associated anomalies in certain syndromal forms which practitioners must be able to recognise. Such investigations facilitate therapeutic indications for forms of haemangioma likely to lead to complications. The most important recent therapeutic development has been the discovery of the spectacular efficacy of beta-blockers (propranolol) upon the development kinetics of infantile haemangioma, greatly transforming the prognosis for these haemangiomas at risk.

The full text of this article is available in PDF format.

Mots clés : Hemangiomes infantiles, Propranolol, Hémangiomatose

Keywords : Infantile haemangioma, Propranolol, Haemangiomatosis




© 2015  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline